Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Pfizer
Aulos Bioscience, Inc.
Essen Biotech
enGene, Inc.
Hoffmann-La Roche
Second Life Therapeutics
Ocellaris Pharma, Inc.
Tyra Biosciences, Inc
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
BicycleTx Limited
BicycleTx Limited
Astellas Pharma Inc
Dana-Farber Cancer Institute
ImmunityBio, Inc.
University of Arizona
Mayo Clinic
University of Texas Southwestern Medical Center
Shanghai Escugen Biotechnology Co., Ltd
Shenzhen Geno-Immune Medical Institute
Palleon Pharmaceuticals, Inc.
Cancer Research UK
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
Lipac Oncology LLC
VA Office of Research and Development
TransThera Sciences (Nanjing), Inc.
Cancer Research UK
NGM Biopharmaceuticals, Inc
Aprea Therapeutics
Sun Yat-sen University
University of Kansas Medical Center